Puma Biotechnology, Inc.
pumabiotechnology.comLive pipeline data from ClinicalTrials.gov, refreshed daily.
Total trials
38
Active
3
Phase 3
2
Total enrollment
8,605
Pipeline matrix
Showing 3 of 3 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Alisertib | — | — | — | — | — | 3 | |
| Paclitaxel | — | — | — | — | 5 | ||
| Endocrine therapy | — | — | — | — | — | 1 |
Next readouts
- 2027-06-30
- 2027-10-30
- 2028-03-31
Top conditions
- Healthy8
- Breast Cancer7
- Advanced Malignant Solid Tumors5
- Advanced Breast Cancer3
- Healthy Subjects3
- Breast Neoplasms3
- Neoplasms2
- HER2+ Metastatic Breast Cancer (MBC)1
Frequently asked questions about Puma Biotechnology, Inc.
- How many clinical trials does Puma Biotechnology, Inc. have on ClinicalTrials.gov?
- Puma Biotechnology, Inc. is listed as the lead sponsor on 38 clinical trials in ClinicalTrials.gov, 3 of which are currently active (recruiting, enrolling, or ongoing).
- How many of Puma Biotechnology, Inc.'s trials are in Phase 3?
- 2 of Puma Biotechnology, Inc.'s trials are in Phase 3, spread across 3 active drug programs.
- What therapeutic areas does Puma Biotechnology, Inc. focus on?
- Puma Biotechnology, Inc.'s most-studied conditions on ClinicalTrials.gov are Healthy, Breast Cancer, Advanced Malignant Solid Tumors, Advanced Breast Cancer, Healthy Subjects.
- When are Puma Biotechnology, Inc.'s next clinical trial readouts?
- Puma Biotechnology, Inc. has 3 upcoming primary-completion readouts tracked here; the soonest is “A Study of Alisertib in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer”, expected around 2027-06-30.